Compare Wahed FTSE USA Shariah ETF (HLAL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Recursion Pharmaceuticals Inc — how do they compare? Wahed FTSE USA Shariah ETF trades at $76 (market cap $1.00B), while Recursion Pharmaceuticals Inc trades at $4.39 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 2.1× Wahed FTSE USA Shariah ETF's market cap, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Wahed FTSE USA Shariah ETF for 65 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| HLAL | RXRX | |
|---|---|---|
Market Cap | $1.00B | $2.14B |
Volume | 51,137 | 30,789,535 |
Sector | Sector/Thematic | Health |
52-Week High | $76.54 | $6.79 |
52-Week Low | $57.46 | $2.84 |
Typical Hold Time | 65 Days | 22 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $76.44, down 0.13% with limited daily movement. The technical picture shows bullish momentum with strong moving average support, though RSI levels above 70 indicate potential overbought conditions. Support and resistance cluster tightly around $76-77, suggesting a critical price zone. Recent corporate actions include a $0.10 dividend scheduled for September 2026.
The stock faces valuation uncertainty with key financial ratios unavailable, requiring deeper fundamental analysis. Technical strength supports near-term upside, but overbought signals and lack of current financial metrics present investment challenges. Investors need updated earnings reports and analyst coverage to assess the company's financial health and growth prospects accurately.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
